Paratek Pharmaceuticals, Inc.
75 Park Plaza
About Paratek Pharmaceuticals, Inc.Paratek Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon its expertise in novel tetracycline chemistry. Paratek's lead product candidate, omadacycline, is the first in a new class of tetracyclines known as aminomethylcyclines, with broad-spectrum activity against Gram-positive, Gram-negative and atypical bacteria.
Omadacycline is a new once-daily oral and IV, well-tolerated broad spectrum antibiotic being developed for use as empiric monotherapy for patients suffering from serious community-acquired bacterial infections, such as acute bacterial skin and skin structure infections, community acquired bacterial pneumonia, urinary tract infections and other community-acquired bacterial infections, particularly when antibiotic resistance is of concern to prescribing physicians.
Paratek's second Phase 3 product candidate, sarecycline, is a well-tolerated, once-daily, oral, narrow spectrum tetracycline-derived antibiotic with potent anti-inflammatory properties for the potential treatment of acne and rosacea in the community setting. Allergan owns the U.S. rights for the development and commercialization of sarecycline. Paratek retains all ex-U.S. rights. Allergan initiated two identical Phase 3 registration studies in December 2014 for sarecycline for the treatment of moderate to severe acne vulgaris. Top line data are expected in the first half of 2017.
Board of Directors Michael F. Bigham Chairman of the Board and Chief Executive Officer
Evan Loh, MD Director and President, Chief Medical Officer
Thomas J. Dietz, Ph.D. Director
Timothy Franson, M.D., Director
Richard Lim Director
Kristine Peterson Director
Robert Radie Director
Jeffrey Stein, Ph.D. Director
Last Updated: 04-23-02
114 articles with Paratek Pharmaceuticals, Inc.
Paratek Pharmaceuticals, Inc. Announces Pricing Of Public Offering Of 2,860,000 Shares Of Common Stock
Paratek Pharmaceuticals, Inc. Adopts Inducement Equity Incentive Plan Under NASDAQ Listing Rule 5635(c)(4)
Paratek Pharmaceuticals, Inc. To Receive $4 Million Payment From Actavis With Initiation Of Phase 3 Trial Of Sarecycline
Transcept Pharmaceuticals, Inc. Declares Special Dividend Of $12.79 Million And Additional Contingent Future Amounts In Connection With Its Merger With Paratek Pharmaceuticals, Inc.
Bay Area's Transcept Pharmaceuticals, Inc. Soars On Plans To Merge With Paratek Pharmaceuticals, Inc., Picks Up $93 Million Along The Way; Transcept Stock Up +19.60% At Market Close (July 1, 2014)
Paratek Pharmaceuticals, Inc. Announces FDA Grant of Qualified Infectious Disease Product (QIDP) Designation for Its Lead Product Candidate, Omadacycline
Paratek Pharmaceuticals, Inc. Announces Appointments of Dennis Molnar as Chief Executive Officer and Director and of Dr. Evan Loh as Chief Medical Officer and Chairman of the Board of Directors
Paratek Pharmaceuticals, Inc. Wins Agreement With FDA on Special Protocol Assessment (SPA) for Phase 3 Study in Community-Acquired Bacterial Pneumonia (CABP)
Paratek Pharmaceuticals, Inc. and Families Of Spinal Muscular Atrophy Announced a Multi-Million Dollar Award from the National Institute of Neurological Diseases and Stroke to Advance a Drug Candidate for Spinal Muscular Atrophy